Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide plus TACE in hepatocellular carcinoma
ChiCTR-TRC-09000523Phase 4Completed
- Sponsor
- First Hospital of China Medical University
- Start
- Sep 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of arsenic trioxide and epirubicin in hepatocellular carcinoma (HCC) (3 arms), sponsored by First Hospital of China Medical University. Primary endpoints: Overall survival, Survival time and 1 more. Started Sep 2009; status: completed.
02
Drugs
arsenic trioxideepirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-09000523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000523.